Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Net Income (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Net Income for 16 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 92.21% to -$1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$901000.0, a 98.11% increase, with the full-year FY2025 number at -$901000.0, up 98.11% from a year prior.
  • Net Income was -$1.5 million for Q4 2025 at Anika Therapeutics, down from $846000.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $15.4 million in Q4 2023 to a low of -$28.1 million in Q3 2024.
  • A 5-year average of -$2.6 million and a median of -$2.0 million in 2024 define the central range for Net Income.
  • Biggest YoY gain for Net Income was 204.95% in 2022; the steepest drop was 856.34% in 2022.
  • Anika Therapeutics' Net Income stood at -$5.8 million in 2021, then surged by 204.95% to $6.1 million in 2022, then soared by 154.1% to $15.4 million in 2023, then crashed by 225.44% to -$19.4 million in 2024, then skyrocketed by 92.21% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Net Income are -$1.5 million (Q4 2025), $846000.0 (Q3 2025), and $677000.0 (Q2 2025).